System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Emmanuelle Barouk-Simonet is an expert in Genetics at Institut Bergonié (France). Emmanuelle Barouk-Simonet has authored 25 publications, the most recent in 2022, and is an investigator in 1 clinical trial. SLR score: 41 (community average: 125). How the SLR is computed.

LeadR Profile

Emmanuelle Barouk-Simonet Institut Bergonié France
41 ScienceLeadR Reputation 41

Unlock

Register Login
Network Map

Genetics

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2013 - 2022
Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 25

Citations

Citations: 580 1st author: 0 Last author: 0 Unique author: 0

Main journals

J Clin Oncol 3
Nat Commun 3
Clin Genet 2
Am J Hum Genet 1
Ann Dermatol Venereol 1

Best Journals

Ann Oncol 1
Nat Genet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition.
PMID 35017683 — incidence, research design, genetic testing, ovarian neoplasms, genes, hereditary breast and ovarian cancer syndrome, high-throughput nucleotide sequencing		J Hum Genet20223
PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas.
PMID 35263698 — breast neoplasms, genes, brca1, mutation		Cancer Genet20222
Further delineation of the NTHL1 associated syndrome: A report from the French Oncogenetic Consortium.
PMID 33454955 — genes, adenomatous polyps, neoplasms, breast, colorectal neoplasms, genetics, medical, colonic neoplasms		Clin Genet202110
Classification of 101 BRCA1 and BRCA2 variants of uncertain significance by cosegregation study: A powerful approach.
PMID 34597585 — genetics, ovary, neoplasms, classification, ovarian neoplasms, breast, genes, brca2, genes, brca1		Am J Hum Genet202123
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant.
PMID 34113011 — heterozygote, breast neoplasms, neoplasms, breast, genes, brca2, genes, brca1, genetics, medical, genetic risk score		Genet Med202137

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1

By status:

Active not recruiting 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 0
multicentric5to9 0
multicentricup10 0

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS